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Summary:  We all experience a host of common life stressors such as the death of a family 
member, medical illness, and financial uncertainty.  While most of us are resilient to such 
stressors, continuing to function normally, for a subset of individuals, experiencing these 
stressors increases the likelihood of developing treatment-resistant, chronic psychological 
problems, including depression and anxiety.  It is thus paramount to identify predictive markers 
of risk, particularly those reflecting fundamental biological processes that can be targets for 
intervention and prevention.  Using data from a longitudinal study of 340 healthy young adults, 
we demonstrate that individual differences in threat-related amygdala reactivity predict 
psychological vulnerability to life stress occurring as much as 1 to 4 years later.  These results 
highlight a readily assayed biomarker, threat-related amygdala reactivity, which predicts 
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psychological vulnerability to commonly experienced stressors and represents a discrete target 
for intervention and prevention. 
Highlights: 
 Amygdala reactivity interacts with stress to predict internalizing symptoms. 
 Amygdala reactivity predicted symptoms as much as 1 to 4 years after scanning. 
eTOC Blurb: Swartz et al. find that individual differences in a readily assayed neural biomarker, 
threat-related amygdala reactivity, predict psychological vulnerability to common life stressors 
as much as 1 to 4 years later. 
 
Introduction 
Exposure to stressful life events is a robust risk factor for the development of treatment-resistant, 
chronic psychological problems including major depression and anxiety disorders (Faravelli, 
1985; Galea et al., 2002; Kendler et al., 1999).  However, whereas most individuals experience 
stressful life events at some point, the lifetime prevalence for major depression and anxiety 
disorders is 17% and 29%, respectively (Kessler et al., 2005), indicating that only a subset of 
individuals experiencing life events will ultimately develop psychopathology.  The ability to 
prospectively identify which individuals are at greatest risk represents a critical gap in our ability 
to effectively intervene and prevent the emergence of disabling psychological problems.  
Focusing such efforts on biological processes involved in stress reactivity and regulation is 
particularly important as they represent not only predictive markers of risk but also discrete 
targets for intervention and prevention.   
 Amygdala reactivity to threat is a prime candidate biomarker for psychological risk to 
common stressors given its critical roles in threat detection, stress reactivity, and memory for 
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negative information (Herman and Cullinan, 1997; Kim et al., 2003; Murty et al., 2010; Pessoa 
and Ungerleider, 2004). Thus, relatively greater amygdala reactivity to common stressors could 
lead to an altered stress response and biased appraisal and memory of stressful events, all of 
which are core symptoms and features of depression and anxiety disorders (Burke et al., 2005; 
Espejo et al., 2012; Fales et al., 2008; Hamilton and Gotlib, 2008).  Not surprisingly, heightened 
threat-related amygdala reactivity is consistently observed in patients with depression and 
anxiety (Etkin and Wager, 2007; Groenewold et al., 2013).  However, cross-sectional research in 
patients cannot determine whether heightened amygdala reactivity is a premorbid vulnerability 
present before the development of symptoms, or whether this neural phenotype is a secondary 
correlate that emerges as a downstream consequence of the onset of symptoms.  Prospective 
research is required to address this limitation and test whether amygdala reactivity predicts 
internalizing symptoms at a future point in time, controlling for baseline symptom levels.   
Adolescents at heightened risk for the development of depression and anxiety through a 
positive family history for these disorders evidence heightened amygdala reactivity to threat 
(Joormann et al., 2012; Monk et al., 2008; Swartz et al., in press), suggesting that this neural 
biomarker can be observed before the onset of disorder.  It remains to be determined, however, 
whether such heightened amygdala reactivity predicts the development of internalizing 
symptoms following the experience of stress in the future.  Indeed, only two studies with small 
samples have examined such a prospective association, with both finding that relatively 
increased amygdala reactivity measured before the experience of a major traumatic event (i.e., 
warzone combat (Admon et al., 2009) or a terrorist attack (McLaughlin et al., 2014)) predicted 
greater subsequent posttraumatic stress disorder symptoms.  While these findings suggest that 
threat-related amygdala reactivity may represent a predictive biomarker of psychological 
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vulnerability to extreme and rare forms of trauma, we do not know if threat-related amygdala 
reactivity has similar predictive utility in the broader population who experience milder forms of 
common stressful life events. 
To examine whether relatively increased threat-related amygdala reactivity prospectively 
predicts psychological vulnerability to common life stressors, we used functional magnetic 
resonance imaging (fMRI) to assess baseline threat-related amygdala reactivity in 753 
participants aged 18-22 years old, all of whom were free of current depression or anxiety 
disorders.  We chose a sample of young adults as this developmental stage marks the beginning 
of a peak period of risk for the emergence of a number of internalizing disorders, including 
major depression, panic disorder, generalized anxiety disorder, and posttraumatic stress disorder 
(Kessler et al., 2005).  A widely utilized and well-established face matching paradigm was used 
to robustly elicit threat-related amygdala reactivity (Nikolova et al., 2014; Prather et al., 2013). 
At the time of scanning, participants reported the number of stressful life events they had 
experienced in the prior year, as well as their experience of childhood trauma and their current 
levels of depression and anxiety symptoms.  We used these baseline measures as covariates in all 
analyses to test whether amygdala reactivity prospectively predicts future psychological 
problems as a function of stress above and beyond participants’ reported symptoms and stress 
levels at baseline. 
  After successful completion of the baseline protocol including fMRI, all participants 
were subsequently contacted by e-mail every 3 months and invited to complete a short online 
assessment of their current mood and experience of stressful life events since their last 
assessment.  At baseline and each follow-up, participants were given a checklist (Clements and 
Turpin, 1996) of stressful life events commonly experienced by students (e.g., death of a very 
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good friend, major car accident, parent losing a job) and were asked to indicate which events had 
occurred since the last assessment as well as the impact of that event.  We calculated the sum of 
all impact scores for each event reported; thus, higher scores can reflect both a greater number of 
events as well as more severe events.  Symptoms of depression and anxiety were reported at 
baseline and each follow-up assessment (Watson et al., 1995). 
Results 
Amygdala reactivity to threat 
Functional MRI results were first examined in SPM8 to ensure that the task elicited predicted 
activation in the amygdala (Figure 1A). As expected, the contrast of fearful and angry faces > 
shapes was associated with bilateral amygdala reactivity: left amygdala, t(810)=28.7, p<.001 
FWE-corrected, peak coordinates (x,y,z): (-22, -6, -18), and right amygdala, t(810)=32.5, p<.001 
corrected, (28, -4, 20). A mean parameter estimate reflecting amygdala reactivity as a function of 
our task (i.e., fearful and angry facial expressions vs. shapes) was extracted for each participant 
and entered into regression models in MPlus v7. 
Model A: Using amygdala reactivity to predict internalizing symptoms as a function of recent 
stress  
To test our hypothesis that baseline threat-related amygdala reactivity predicts 
psychological vulnerability to the subsequent experience of common life stressors at any point in 
the future, we first created a model (Model A; Figure 1B) using the largest sample of participants 
that completed an online assessment at any time post-scanning.  For participants that completed 
multiple assessments, we selected data from the most recent assessment available.  Follow-up 
assessments were available from a total of 340 participants, and were collected approximately 1 
year post-scanning (M=468 days, Min-Max=90-1402).  Model A was significant (Table S1; 
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p<.001), with the interaction between amygdala reactivity and life stress reported post-scanning 
predicting the severity of symptoms (B=2.01, SE=.7, t(339)=3.08, p=.002).  Specifically, 
individuals with relatively heightened amygdala reactivity at baseline who also reported 
experiencing greater life stress subsequent to scanning had significantly greater symptoms at 
follow-up (Figure 1C and Figure S1). Exploratory whole-brain results are reported in Table S2. 
Model B: Long-term predictive utility of amygdala reactivity 
While Model A confirmed our hypothesis that amygdala reactivity represents a predictive 
biomarker of psychological vulnerability to common life stressors, this model included 
participants who completed post-scanning assessments in relatively close proximity to the scan 
(e.g., 3 months).  To determine the long-term predictive utility of threat-related amygdala 
reactivity, we next analyzed data from only those participants who completed an online 
assessment at least one year post-scanning (Model B; Figure 2A).  For this model, 192 
participants were included who completed their assessment on average 2 years post-baseline 
(M=683 days, Min-Max=365-1402).  Model B was significant (Table S3; p<.001), with the 
interaction between amygdala reactivity and life stress predicting symptom severity following 
stress occurring approximately 2 years later (B=1.75, SE=.8, t(191)=2.33, p=.02).  Again, 
participants with relatively heightened amygdala reactivity at baseline who experienced 
relatively high life stress post-scanning reported the greatest symptoms (Figure 2B and Figure 
S2).  
Model C: Prospective assessment of stressful life events 
A limitation of our previous models is that we used concurrent reports of life stress and 
internalizing symptoms from the most recent assessment available.  Participants experiencing 
greater negative affect at the time of assessment may be biased toward indicating greater severity 
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of recent life stress.  Therefore, we created a final model (Model C, Figure 3A) in which life 
stress was assessed prospective to the reporting of symptoms.  To equate participants in terms of 
when stressful life events and symptoms were measured, we obtained symptoms from 
assessments completed approximately 1 year post-scanning.  We then computed the mean life 
stress score for all assessments completed prior to this, yielding a prospective set of variables 
including threat-related amygdala reactivity at baseline, life stress that occurred post-scanning, 
and symptoms approximately 1 year post-scanning.  Data from 99 participants were available for 
this analysis.  The moderation Model C was significant (Table S3; p<.001), indicating a 
significant interaction between threat-related amygdala reactivity and subsequent life stress in 
predicting internalizing symptoms 1 year later (B=5.56, SE=1.9, t(98)=2.96, p=.003).  As in our 
previous models, individuals with relatively heightened amygdala reactivity who experienced 
greater life stress post-scanning reported greater internalizing symptoms 1 year later (Figure 3B 
and Figure S3).  The interaction between amygdala reactivity and life stress explained an 
additional 5% of the variance in symptoms, above and beyond all covariates, including 
symptoms reported at baseline.   
Discussion 
Using data from a large longitudinal study of healthy young adults, we provide novel evidence 
for the utility of threat-related amygdala reactivity - assessed with fMRI - as a predictive 
biomarker of risk for broad psychological vulnerability to commonly experienced stressful life 
events.  Our neural risk biomarker predicted vulnerability consistent with a diathesis-stress 
model in both the short- and long-term as well as independently of negative reporting biases.  
Critically, we did not find a main effect of amygdala reactivity in predicting future internalizing 
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symptoms, indicating that this neural biomarker predicts greater symptoms only within the 
context of experiencing relatively high life stress. 
 Remarkably, amygdala reactivity measured at one time point significantly predicted 
internalizing symptoms, above and beyond baseline symptoms, as much as 1 to 4 years into the 
future, indicating possible utility of this neural phenotype for prediction of long-term 
internalizing outcomes.  However, it is important to note that the interaction between amygdala 
reactivity and stress only explained an additional 1-5% of the variance in symptoms, with the 
long-term model (Model B) evidencing the weakest effect.  There are several methodological 
limitations of the current study that may have led us to underestimate the size of this effect.  
First, participants were not guaranteed payment for completing follow-up online assessments but 
entered into a larger gift card raffle.  Thus, missing data may have biased our results.  Second, 
life stress was assessed through a self-report checklist rather than through a more objective 
approach such as a calendar interview.  Third, our non-clinical sample of undergraduate students 
was generally low-risk and the associated range and variability in internalizing symptoms 
truncated in comparison to clinical or high-risk samples.  We anticipate that future research 
addressing these limitations may find larger effect sizes than those reported in the present study.  
Nevertheless, these results underscore the need to identify additional biomarkers, whether neural 
or genetic, that can explain additional variance in addition to or in interaction with that accounted 
for by threat-related amygdala reactivity. 
Notably, a range of previously identified risk factors for depression and anxiety disorders 
are all associated with relatively increased amygdala reactivity to threat (Bogdan et al., 2012; 
Swartz et al., in press; Nikolova et al., 2014; White et al., 2012), and our biomarker is consistent 
with specific pathways of increased risk, including exaggerated hypothalamic-pituitary-adrenal 
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axis stress responsiveness and cognitive biases.  Although our follow-up assessments did not 
allow for direct mapping of threat-related amygdala reactivity onto formal clinical diagnosis, the 
increased stress-related symptoms of depression and anxiety predicted by amygdala reactivity 
have been directly associated with dysfunction (Bredemeier et al., 2010; Buckby et al., 2007), 
and relatively increased amygdala reactivity is consistently observed in patients with clinical 
depression and anxiety disorders (Etkin and Wager, 2007; Groenewold et al., 2013).  Thus, 
threat-related amygdala reactivity represents a predictive neural biomarker through which a 
range of risk factors may create a common diathesis for psychological vulnerability to the 
experience of common life stressors in the general population.  As such, relatively increased 
threat-related amygdala reactivity further represents a discrete biological mechanism that can be 
targeted in the development of novel strategies for more effective prevention of otherwise 
chronic and treatment-resistant psychiatric disorders.  The amygdala, of course, represents only 
one node of an extended corticolimbic circuit supporting emotion processing and stress 
responsiveness.  Other circuit nodes include the hypothalamus, brainstem, insula, hippocampal 
formation, and prefrontal cortex.  Future research using paradigms designed to target these other 
circuit nodes as well as their dynamic interactions may further illuminate biological pathways 
through which individual differences in stress responsiveness may eventually manifest as 
disorder. 
 
Experimental Procedures 
Participants 
Young adult college students were recruited as part of the Duke Neurogenetics Study.  All 
procedures were approved by the Duke University Medical Center and participants provided 
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informed consent before participating in the study.  Participants were included in the present 
sample if they met the following criteria: 1) free of medical diagnoses of cancer, stroke, diabetes, 
chronic kidney or liver disease, or lifetime history of psychotic symptoms; 2) no use of 
psychotropic, glucocorticoid, or hypolipidemic medication; 3) no conditions affecting cerebral 
blood flow and metabolism (e.g., hypertension); and 4) met quality control criteria for functional 
MRI scanning. Moreover, due to our interest in predicting internalizing symptoms post-scanning, 
we excluded any participants with a current mood, anxiety, or eating disorder diagnosis at the 
time of scanning, based on the electronic Mini International Neuropsychiatric Interview 
(Sheehan et al., 1998).  A covariate was included in all analyses to control for participants with a 
non-internalizing diagnosis (e.g., substance abuse) or with a past internalizing diagnosis. A total 
of 811 participants met inclusion criteria for the imaging data (see Supplemental Experimental 
Procedures for quality control criteria), 57 were excluded for current psychopathology, and 1 
participant was missing data, leaving 753 participants (57% female) ranging in age from 18 to 22 
available for analyses (Table 1). 
 
Measures: Baseline Assessments 
 
Functional MRI 
Participants performed a face matching task that has been to shown to elicit robust amygdala 
reactivity across a range of studies and samples, including the present sample (Nikolova et al., 
2014; Prather et al., 2013). The current paradigm consisted of four blocks of face matching 
interleaved with five blocks of a shape-matching sensorimotor control task. During face-
matching blocks, participants viewed a trio of faces and selected one of two faces (on bottom) 
matching a target face (on top).  Each face block contained one of the following expressions: 
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fearful, angry, surprised, and neutral.  Each trial in the face-matching blocks lasted for 4 seconds 
with a variable interstimulus interval (ISI) of 2 to 6 seconds (M=4 seconds), for a total block 
length of 48 seconds. In the control blocks, each of the six shape trios was presented for 4 
seconds with a fixed ISI of 2 seconds, for a total block length of 36 seconds. Total task time was 
390 seconds.  Details regarding fMRI acquisition are reported in the Supplemental Experimental 
Procedures. 
 
Covariates 
Because we were interested in predicting the future development of internalizing symptoms, we 
controlled for internalizing symptoms at baseline using the Mood and Anxiety Symptoms 
Questionnaire (MASQ) Short Form (Watson et al., 1995). Scores across all subscales (general 
distress/depression, general distress/anxiety, anxious arousal, and anhedonia) were summed to 
create a measure of total internalizing symptoms.  Likewise, because we were interested in the 
effect of life stress occurring post-scanning, we controlled for life stress reported at baseline.  To 
assess life stress, participants were administered the Life Events Scale for Students (LESS; 
Clements and Turpin, 1996), to measure the number of life events that occurred in the past 12 
months. Participants also rated the impact that the life event had on them on a 1 to 4 scale 
(4=severe impact). The impact score for each event reported was summed to yield a LESS total 
impact score; higher values indicate both greater number and severity of life events. Additional 
covariates are described in the Supplement. 
 
Measures: Post-scanning assessments 
Participants were re-contacted post-scanning to complete follow-up assessments online every 3 
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months.  Successful completers were entered into a raffle for one $50 Amazon gift card for each 
round of follow-up assessments.  The same questions from the LESS were used to assess 
stressful life events in the post-scanning questionnaires; however, for these assessments 
participants were asked to report if any life events had occurred since their last assessment.  
Participants also completed the MASQ Short Form during these post-scanning assessments.  In 
accordance with our first model (Model A), we selected the most recent assessment available for 
all participants, and obtained the life stress total impact score from the LESS and total 
internalizing symptoms from the MASQ at this most recent assessment.  For Model B, we took a 
similar approach, except that we limited this model to those participants who had completed an 
assessment at least 1 year post-scanning.  In accordance with our final model (Model C), we 
selected MASQ symptom scores from questionnaires completed approximately 1 year post-
scanning (the inclusion range was set to 365-455 days post-scanning, to take into account the fact 
that participants may not have completed the assessment exactly 365 days post-scanning). We 
then computed the mean of the LESS impact score from each assessment completed before that 
(Figure 3A).  Extra care was taken in quality control procedures for these assessments, given that 
they were administered online. Specifically, individual item responses were examined for any 
obvious patterns of false reporting (e.g., a participant indicates a yes for every stressful life event 
on the LESS).  Attrition analyses are reported in the Supplemental Experimental Procedures.    
 
Analyses 
Functional MRI 
 
Functional MRI data were processed in SPM8 using the standard pre-processing stream used in 
previously published research from the Duke Neurogenetics Study. Further details on the 
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procedure and quality control criteria are reported in the Supplemental Experimental Procedures.  
We hypothesized that results would be specific to threatening facial expressions (fearful and 
angry), thus the main contrast analyzed was fearful and angry faces > shapes. To examine the 
specificity of effects to negative expressions, we also ran analyses with parameter estimates for 
amygdala reactivity to neutral faces > shapes as a control condition, reported in the Supplemental 
Data.  To obtain estimates of amygdala reactivity for each condition, we first identified 
functional clusters within the amygdala (defined structurally with the Automated Anatomical 
Labeling atlas) activated at p<.05 family-wise error (FWE) corrected within the region of interest 
for each condition in SPM8.  Then, we extracted parameter estimates for the left and right 
amygdala for each condition.  This procedure has been used in prior published research from the 
Duke Neurogenetics Study (Nikolova et al., 2012; Nikolova et al., 2014).  Because left and right 
amygdala reactivity for our contrast of interest (fearful and angry faces>shapes) was highly 
correlated (r=.78, p<.001), we averaged across hemispheres to obtain one mean parameter 
estimate of amygdala reactivity and reduce the number of comparisons performed. 
 
Moderation model 
Our hypothesis was that the association between amygdala reactivity and internalizing symptoms 
would be moderated by the amount of life stress experienced post-scanning.  After parameter 
estimates of amygdala reactivity were extracted in SPM8, all subsequent analyses to test this 
proposed moderation model were performed in MPlus version 7.  Thus, for Models A-C, MASQ 
total scores from the follow-up assessment were entered as the dependent variable, and extracted 
parameter estimates of amygdala reactivity, the total life stress impact score from follow-up, and 
the interaction between these were entered as predictors. The following were included as 
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covariates: age at the most recent assessment, gender, childhood trauma total scores, LESS total 
impact scores from the baseline assessment, MASQ total scores at baseline, the psychopathology 
covariate, days between scanning and completing the follow-up questionnaire, and (for Model C 
only) the number of assessments contributing to the mean LESS total impact score.  Predictors 
were mean-centered.  Because symptoms at Time 2 were moderately skewed, MLR estimation 
was specified to estimate standard errors robust to non-normality. 
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Figure and Table Legends 
Fig. 1. Model A: All participants completing a post-scanning assessment (n=340). (A) 
Participants underwent a baseline fMRI scan to measure threat-related amygdala reactivity.  The 
main effect of task (fearful and angry faces>shapes) elicited bilateral amygdala reactivity 
(thresholded at p<.05 corrected). (B) Participants were invited to complete an online assessment 
every 3 months post-scanning.  The green boxes indicate the baseline scanning assessment and 
the blue boxes indicate online assessments.  For Model A, life stress at Time 2 (as measured by 
the Life Events Scale for Students) and internalizing symptoms at Time 2 (as measured by the 
Mood and Anxiety Symptom Questionnaire) were taken from the most recent assessment 
completed by each participant, as indicated by the red boxes.  (C) Depressive and anxiety 
symptoms at Time 2 are plotted as a function of the parameter estimates of threat-related 
amygdala reactivity and life stress post-scanning (groups divided into terciles).  Dotted lines 
indicate 95% confidence bands.  Internalizing symptoms were predicted by a significant 
interaction between amygdala reactivity and life stress experienced post-scanning, B=2.01, 
SE=.7, t(339)=3.08, p=.002.  See also Table S1 and Figure S1. 
 
Fig. 2. Model B: All participants completing an assessment at least 1-year post-scanning 
(n=192). (A) For Model B, we selected data from all participants who completed a follow-up 
assessment at least 1 year post-scanning. (B) Internalizing symptoms at Time 2 as a function of 
amygdala reactivity and life stress experienced post-scanning.  Internalizing symptoms were 
predicted by a significant interaction between amygdala reactivity and life stress experienced 
post-scanning, B=1.75, SE=.8, t(191)=2.33, p=.02. See also Table S3 and Figure S2. 
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Fig. 3. Model C: Predicting symptoms reported approximately 1 year post-scanning from 
amygdala reactivity at baseline and life stress reported between the scanning session and 1 
year post-scanning (n=99).  (A) For Model C, to obtain a prospective assessment of life stress, 
we selected depression and anxiety symptoms from the assessment completed approximately 1 
year post-scanning (range: 365-455 days) and a mean stress score from all assessments 
completed before then.  (B) Internalizing symptoms at Time 2 as a function of amygdala 
reactivity and life stress experienced post-scanning (groups created by median split).  
Internalizing symptoms were predicted by a significant interaction between amygdala reactivity 
and life stress experienced post-scanning, B=5.56, SE=1.9, t(98)=2.96, p=.003. See also Table 
S3 and Figure S3. 
 
Table 1. Participant characteristics. Childhood trauma=Total of all subscales of the Childhood 
Trauma Questionnaire; Stressful life events=Total impact score for all life events reported on the 
Life Events Scale for Students; Internalizing symptoms=Total of all subscales on the Mood and 
Anxiety Symptoms Questionnaire; SD=standard deviation. 
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Table 1 Participant Characteristics 
 Mean SD Min Max 
Baseline (n=753) 
Age (years) 19.6 1.2 18 22 
Childhood trauma 33.2 7.9 25 75 
Stressful life events Time 1 10.1 8.2 0 66 
Internalizing symptoms Time 1 110.7 25.4 61 230 
Time 2 Scores: Model A (n=340) 
Age (years) 20.8 1.5 18 26 
Stressful life events Time 2  4.3 5.3 0 34 
Internalizing symptoms Time 2 110.7 26.4 65 214 
Days between imaging and assessment 467.6 326.7 90 1402 
Time 2 Scores: Model B (n=192) 
Age (years) 21.4 1.4 19 26 
Stressful life events Time 2 5.4 6.2 0 34 
Internalizing symptoms Time 2 111.6 27.2 65 211 
Days between imaging and assessment 683.0 278.6 365 1402 
Time 2 Scores: Model C (n=99) 
Age (years) 20.5 1.1 19 23 
Stressful life events Time 2 3.3 4.2 0 27.7 
Internalizing symptoms Time 2 109.9 29.2 65 230 
Days between imaging and assessment 397.3 39.2 365 455 
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Figure 1 
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Figure 2 
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Figure 3 
 
 
